News

Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference

Presentation
on Tuesday December 15th  at
10:40am EST

LOS ANGELES, CA – (NewMediaWire) – December 08, 2020 – Timber Pharmaceuticals,
Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and commercialization of
treatments for rare and orphan dermatologic diseases, today announced that it
will be presenting at the 13th annual LD Micro Main Event investor conference
on Tuesday, December 15, 2020 at 10:40 AM EST / 7:40 AM PST. John Koconis,
Chief Executive Officer of Timber Pharma, will be presenting to a live, virtual
audience. 

Register
here: 
ve.mysequire.com/

The Main
Event will feature a new and unique format, with companies presenting for 10
minutes, followed by 10 minutes of Q&A by a panel of investors and
analysts. 

“The
time has finally come to do something different in the virtual conference
world. Let’s see if we can pull off something that can be enjoyed by both
executives and investors alike,” stated Chris Lahiji, Founder of LD, now a
wholly owned subsidiary of SRAX, Inc.

The Main
Event will take place on December 14th and 15th, exclusively on the Sequire
Virtual Events platform. 

View Timber
Pharmaceuticals profile here: http://www.ldmicro.com/profile/TMBR

Profiles
powered 
by LD
Micro

About
Timber Pharmaceuticals, Inc.

Timber
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development
and commercialization of treatments for rare and orphan dermatologic diseases.
The Company’s investigational therapies have proven mechanisms-of-action backed
by decades of clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles. The Company is initially
focused on developing non-systemic treatments for rare dermatologic diseases
including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and localized scleroderma. For more information,
visit 
www.timberpharma.com.

About LD
Micro/SEQUIRE

LD Micro
began in 2006 with the sole purpose of being an independent resource to the
microcap world. What started as a newsletter highlighting unique companies, has
transformed into the pre-eminent event platform in the space. For more
information, please visit 
ldmicro.com.

The
upcoming Main Event will be highlighting a new format that will benefit both
executives and the investors tuning in from all over the globe. 

In
September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial
technology company that unlocks data and insights for publicly traded
companies. Through its premier investor intelligence and communications
platform, 
Sequire, companies can track their investors’
behaviors and trends and use those insights to engage current and potential investors
across marketing channels. For more information on SRAX, visit 
srax.com and mysequire.com.

Forward-Looking
Statements

This press
release contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended,
including those relating to the Company’s product development, clinical and
regulatory timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies, potential growth
opportunities and other statements that are predictive in nature. These
forward-looking statements are based on current expectations, estimates,
forecasts and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions.

These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,”
“estimate,” “potential, “predict,”
“project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Form 10-Q filed on August 18,
2020 and its other filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.

For more
information, contact:

 

Timber
Pharmaceuticals, Inc. 

John
Koconis 

Chief
Executive Officer

jkoconis@timberpharma.com

 

Investor
Relations:

Stephanie
Prince

PCG
Advisory

(646)
762-4518

sprince@pcgadvisory.com

 

Media
Relations: 

Adam Daley

Berry &
Company Public Relations 

(212)
253-8881

adaley@berrypr.com

 

Source: Timber
Pharmaceuticals via LD Micro 

Source link

Tags
Show More

Related Articles

Back to top button
Close

Get Smallcap and Microcap News, Research, Trade Alerts & MORE, all 100% FREE!

Enter your email address to get started. All 100% Free.

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@smallcapsdaily.com